Company Overview and News

13
10
36
7 Biotech Stocks Insiders Are Loading Up On

2018-08-22 247wallst - 12
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports.
OCUL RIGL VYGR CORT LJPC ATNX SRPT

6
OCUL / Ocular Therapeutix, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
ocul_Current_Folio_June 30, 2018 Table of Contents
OCUL

55
Your Daily Pharma Scoop: Jazz Reports Mixed Bag, Roche And Takeda Positive

2018-07-23 seekingalpha
Discussion: Jazz Pharmaceuticals (JAZZ) announced publication of the pivotal Phase 3 trial of Vyexos (daunorubicin and cytarabine) liposome for injection compared to standard of care (‘SOC) cytarabine and daunorubicin (7+3) in the Journal of Clinical Oncology. Vyxeos is a fixed combination of daunorubicin and cytarabine for intravenous liposome injection available in 44/ 100 mg variants. Vyexos was approved by the FDA a year ago in August 2017.
OCUL SNGX JAZZ AGN MRK IDXG CRBP AMD LLY PFE BMY

6
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

2018-07-19 zacks
Ocular Therapeutix, Inc. (OCUL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because OCUL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
OCUL

24
Abbott (ABT) Beats on Earnings and Revenues in Q2

2018-07-18 zacks
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
ABT OCUL JAKK FTRPR ABT FTR

17
Grupo Simec (SIM) Catches Eye: Stock Jumps 7.1%

2018-07-18 zacks
Grupo Simec, S.A.B. de C.V. (SIM - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 17.1% in the past one-month time frame.
OCUL JAKK MT FTRPR MT FTR

18
Should You Buy E*TRADE (ETFC) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season E*TRADE Financial Corporation (ETFC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR ETFC FTR

17
Should You Buy Union Pacific (UNP) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Union Pacific Corporation (UNP - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR UNP FTR

17
Why Earnings Season Could Be Great for Blackstone (BX)

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and The Blackstone Group L.P. (BX - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL JAKK FTRPR FTR

61
Luminex (LMNX) Looks Good: Stock Adds 5.7% in Session

2018-07-18 zacks - 1
Luminex Corporation (LMNX - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 10.9% in the past one-month time frame.
OCUL JAKK FTRPR LMNX CHEK CHEKW FTR

17
Is a Surprise Coming for Cintas (CTAS) This Earnings Season?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Cintas Corporation (CTAS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
OCUL CTAS JAKK FTRPR FTR

OCUL : Ocular Therapeutix Stock Analysis and Research Report

2017-10-19 - Asif

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. Its intracanalicular inserts combine its hydrogel technology with U.S. Food and Drug Administration, or FDA, approved therapeutic agents with the goal of providing extended delivery of drug to the eye. Ocular also has...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to OCUL / Ocular Therapeutix, Inc. on message board site Silicon Investor.

Ocular Sciences (OCLR) Ocular Sciences (OCLR) Ocular Sciences (OCLR)
CUSIP: 67576A100